Gemini Therapeutics, Inc.
NASDAQ: GMTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $25.5M
- Website
- https://www.geminitherapeutics.com
Loading GMTX…
Loading profile data…Frequently asked questions about GMTX
What does Gemini Therapeutics, Inc. (GMTX) do?
Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients....
Where does GMTX trade?
Gemini Therapeutics, Inc. (GMTX) trades on the NASDAQ Global Market.
What sector is GMTX in?
Gemini Therapeutics, Inc. (GMTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Where is Gemini Therapeutics, Inc. headquartered?
Gemini Therapeutics, Inc. is headquartered in United States.
Does GMTX pay a dividend?
Gemini Therapeutics, Inc. (GMTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GMTX go public?
Gemini Therapeutics, Inc. (GMTX) completed its initial public offering in 2020.